Takeda will work with University College London to study the potential of induced pluripotent stem cells in the treatment of patients with muscular dystrophy. The $250,000 fund from Takeda's New Frontier Science group will also be used to explore new muscular dystrophy treatments through gene and cell therapy techniques using novel biomaterials and artificial human chromosomes.

Related Summaries